Posted by Michael Wonder on 15 Nov 2023
FDA approves new drug under special pathway for patients receiving haemodialysis
15 November 2023 - The US FDA has approved Defencath (taurolidine and heparin) catheter lock solution to reduce catheter-related bloodstream infections in adult patients with kidney failure who are receiving chronic haemodialysis through a central venous catheter.
Defencath is indicated in this limited and specific patient population.
